FDA Issues Guidance on Expedited Pathways for Cell Therapies

Drug Industry Daily
A A
The FDA released final guidance outlining the expedited pathways available to sponsors of regenerative medicine therapies — including considerations for clinical trial designs for treatments of rare diseases.

To View This Article:

Login

Subscribe To Drug Industry Daily